Jump to ContentJump to Main Navigation
Show Summary Details

Journal of Pediatric Endocrinology and Metabolism

Editor-in-Chief: Kiess, Wieland

Ed. by Bereket, Abdullah / Cohen, Pinhas / Darendeliler, Feyza / Dattani, Mehul / Gustafsson, Jan / Luo, Feihong / Mericq, Veronica / Roth, Christian / Toppari, Jorma

Editorial Board Member: Battelino, Tadej / Buyukgebiz, Atilla / Cassorla, Fernando / Chrousos, George P. / Cutfield, Wayne / Fideleff, Hugo L. / Hershkovitz, Eli / Hiort, Olaf / LaFranchi, Stephen H. / Lanes M. D., Roberto / Mohn, Angelika / Root, Allen W. / Rosenfeld, Ron G. / Werther, George / Zadik, Zvi

IMPACT FACTOR 2015: 0.912

SCImago Journal Rank (SJR) 2015: 0.493
Source Normalized Impact per Paper (SNIP) 2015: 0.600
Impact per Publication (IPP) 2015: 0.955

149,00 € / $224.00 / £112.00*

See all formats and pricing


Select Volume and Issue


Children at risk of diabetes type 1. Treatment with acetyl-L-carnitine plus nicotinamide – Case reports

Ivana Cristina Fernandez2 / María del Carmen Camberos1 / Gisel Anabel Passicot1 / Lucía Camila Martucci1 / 3

1Endocrinology Research Center (CEDIE-CONICET), Endocrinology Division, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina

2Diabetes Division, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina

3Endocrinology Research Center (CEDIE-CONICET), Htal. de Niños “R. Gutiérrez”, Gallo 1330 (1425), Buenos Aires, Argentina

Corresponding author: Juan Carlos Cresto, MD, PhD, Endocrinology Research Center (CEDIE-CONICET), Htal. de Niños “R. Gutiérrez”, Gallo 1330 (1425), Buenos Aires, Argentina Phone: 054-11-4963-5931 int. 123, Fax: 054-11-4963-5930

Citation Information: Journal of Pediatric Endocrinology and Metabolism. Volume 26, Issue 3-4, Pages 347–355, ISSN (Online) 2191-0251, ISSN (Print) 0334-018X, DOI: 10.1515/jpem-2012-0128, June 2012

Publication History

Published Online:


Objectives: The aim was to evaluate the treatment with acetyl-L-carnitine (50 mg/kg/day) and nicotinamide (25 mg/kg/day) in children at risk of type 1 diabetes. This treatment was effective and harmless in experimental type 1 diabetes in mice.

Patients: Nine out of seventy healthy participants of the type 1 diabetes risk study were treated. They were typified for diabetes with HLA-DQB1 and positive autoantibodies. Children with a first peak of insulin response ≤48 µU were randomly distributed in control and treated patients. Children evolution was followed with an intravenous glucose tolerance test. Control children were treated when was another risk parameter was added. During their evolution all children were treated.

Results: Treatment periods differ (range: 120–16 months) because children began treatment at different times. During the treatment 4 patients recovered their parameters and the medication was suspended; 2 patients continued the treatment with favorable evolution. Two children evolved slowly with normal growth and development. One girl became diabetic because she was treated late.

Conclusions: In children at risk, this treatment delays the development or remits the evolution of type 1 diabetes

Keywords: acetyl-L-carntine plus nicotinamide treatment; intravenous glucose tolerance test; longitudinal study; patients at risk of type 1 diabetes

Comments (0)

Please log in or register to comment.